1
|
de Aquino TM, França PHB, Rodrigues ÉEES, Nascimento IJS, Santos-Júnior PFS, Aquino PGV, Santos MS, Queiroz AC, Araújo MV, Alexandre-Moreira MS, Rodrigues RRL, Rodrigues KAF, Freitas JD, Bricard J, Meneghetti MR, Bourguignon JJ, Schmitt M, da Silva-Júnior EF, de Araújo-Júnior JX. Synthesis, Antileishmanial Activity and in silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes. Med Chem 2021; 18:151-169. [PMID: 33593264 DOI: 10.2174/1573406417666210216154428] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 12/14/2020] [Accepted: 12/15/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most severe, fatal in 95% of cases. The undesired side-effects from first-line chemotherapy and the reported drug resistance search for effective drugs that can replace or supplement those currently used an urgent need. Aminoguanidine hydrazones (AGH's) have been explored for exhibiting a diverse spectrum of biological activities, in particular the antileishmanial activity of MGBG. The bioisosteres thiosemicarbazones (TSC's) offer a similar biological activity diversity, including antiprotozoal effects against Leishmania species and Trypanosoma cruzi. OBJECTIVE Considering the impact of leishmaniasis worldwide, this work aimed to design, synthesize, and perform a screening upon L. chagasi amastigotes and for the cytotoxicity of the small "in-house" library of both AGH and TSC derivatives and their structurally-related compounds. METHOD A set of AGH's (3-7), TSC's (9, 10), and semicarbazones (11) were initially synthesized. Subsequently, different semi-constrained analogs were designed and also prepared, including thiazolidines (12), dihydrothiazines (13), imidazolines (15), pyrimidines (16, 18) azines (19, 20), and benzotriazepinones (23-25). All intermediates and target compounds were obtained with satisfactory yields and exhibited spectral data consistent with their structures. All final compounds were evaluated against L. chagasi amastigotes and J774.A1 cell line. Molecular docking was performed towards trypanothione reductase using GOLD® software. RESULT The AGH's 3i, 4a, and 5d, and the TSC's 9i, 9k, and 9o were selected as valuable hits. These compounds presented antileishmanial activity compared with pentamidine, showing IC50 values ranged from 0.6 to 7.27 μM, maximal effects up to 55.3%, and satisfactory SI values (ranged from 11 to 87). On the other hand, most of the resulting semi-constrained analogs were found cytotoxic or presented reduced antileishmanial activity. In general, TSC class is more promising than its isosteric AGH analogs, and the beneficial aromatic substituent effects are not similar in both series. In silico studies have suggested that these hits are capable of inhibiting the trypanothione reductase from the amastigote forms. CONCLUSION The promising antileishmanial activity of three AGH's and three TSC's was characterized. These compounds presented antileishmanial activity compared with PTD, showing IC50 values ranged from 0.6 to 7.27 μM, and satisfactory SI values. Further pharmacological assays involving other Leishmania strains are under progress, which will help to choose the best hits for in vivo experiments.
Collapse
Affiliation(s)
- Thiago M de Aquino
- Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| | - Paulo H B França
- Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| | - Érica E E S Rodrigues
- Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| | - Igor J S Nascimento
- Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| | - Paulo F S Santos-Júnior
- Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| | - Pedro G V Aquino
- Federal Rural University of Pernambuco, Garanhuns-PE, 55292-270. Brazil
| | - Mariana S Santos
- Federal Rural University of Pernambuco, Garanhuns-PE, 55292-270. Brazil
| | - Aline C Queiroz
- Laboratory of Pharmacology and Immunology, Institute of Biological and Health Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| | - Morgana V Araújo
- Laboratory of Pharmacology and Immunology, Institute of Biological and Health Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| | - Magna S Alexandre-Moreira
- Laboratory of Pharmacology and Immunology, Institute of Biological and Health Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| | - Raiza R L Rodrigues
- Laboratory of Infectious Diseases, Federal University of Parnaíba Delta, 64202-020, Parnaíba-PI. Brazil
| | - Klinger A F Rodrigues
- Laboratory of Infectious Diseases, Federal University of Parnaíba Delta, 64202-020, Parnaíba-PI. Brazil
| | - Johnnatan D Freitas
- Instrumental Analysis Laboratory, Federal Institute of Alagoas, Campus Maceió, Ferroviário Avenue, 57020-600, Maceió-AL. Brazil
| | - Jacques Bricard
- Laboratoire d'Innovation thérapeutique, UMR 7200, Labex Medalis, CNRS, Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, BP 60024, 67401 Illkirch. France
| | - Mario R Meneghetti
- Institute of Chemistry and Biotechnology, Federal University of Alagoas, 57072-90 0, Maceió-AL. Brazil
| | - Jean-Jacques Bourguignon
- Laboratoire d'Innovation thérapeutique, UMR 7200, Labex Medalis, CNRS, Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, BP 60024, 67401 Illkirch. France
| | - Martine Schmitt
- Laboratoire d'Innovation thérapeutique, UMR 7200, Labex Medalis, CNRS, Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, BP 60024, 67401 Illkirch. France
| | - Edeildo F da Silva-Júnior
- Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| | - João X de Araújo-Júnior
- Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, 57072-900, Maceió-AL. Brazil
| |
Collapse
|
2
|
Castro HC, Abreu PA, Geraldo RB, Martins RCA, dos Santos R, Loureiro NIV, Cabral LM, Rodrigues CR. Looking at the proteases from a simple perspective. J Mol Recognit 2011; 24:165-81. [PMID: 21360607 DOI: 10.1002/jmr.1091] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Proteases have received enormous interest from the research and medical communities because of their significant roles in several human diseases. Some examples include the involvement of thrombin in thrombosis, HIV-1 protease in Acquired Immune Deficiency Syndrome, cruzain in Trypanosoma cruzi infection, and membrane-type 1 matrix metalloproteinase in tumor invasion and metastasis. Many efforts has been undertaken to design effective inhibitors featuring potent inhibitory activity, specificity, and metabolic stability to those proteases involved in such pathologies. Protease inhibitors usually target the active site, but some of them act by other inhibitory mechanisms. The understanding of the structure-function relationships of proteases and inhibitors has an impact on new inhibitor drugs designing. In this paper, the structures of four proteases (thrombin, HIV-protease, cruzain, and a matrix metalloproteinase) are briefly reviewed, and used as examples of the importance of proteases for the development of new treatment strategies, leading to a longer and healthier life.
Collapse
Affiliation(s)
- Helena C Castro
- LABioMol, Departamento de Biologia Celular e Molecular, Instituto de Biologia, Universidade Federal Fluminense, Rio de Janeiro, 24001-970, Brazil.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Andersen R, Nielsen CU, Begtrup M, Jørgensen FS, Brodin B, Frokjaer S, Steffansen B. In vitro evaluation of N-methyl amide tripeptidomimetics as substrates for the human intestinal di-/tri-peptide transporter hPEPT1. Eur J Pharm Sci 2006; 28:325-35. [PMID: 16713701 DOI: 10.1016/j.ejps.2006.03.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2005] [Revised: 02/22/2006] [Accepted: 03/21/2006] [Indexed: 10/24/2022]
Abstract
Oral absorption of tripeptides is generally mediated by the human intestinal di-/tri-peptide transporter, hPEPT1. However, the bioavailability of tripeptides is often limited due to degradation in the GI-tract by various peptidases. The aim of the present study was to evaluate the general application of N-methyl amide bioisosteres as peptide bond replacements in tripeptides in order to decrease degradation by peptidases and yet retain affinity for and transport via hPEPT1. Seven structurally diverse N-methyl amide tripeptidomimetics were selected based on a principal component analysis of structural properties of 6859 N-methyl amide tripeptidomimetics. In vitro extracellular degradation of the selected tripeptidomimetics as well as affinity for and transepithelial transport via hPEPT1 were investigated in Caco-2 cells. Decreased apparent degradation was observed for all tripeptidomimetics compared to the corresponding natural tripeptides. However, affinity for and transepithelial transport via hPEPT1 were only seen for Gly-Sar-Sar, AsnPsi[CONCH(3)]PhePsi[CONCH(3)]Trp, and Gly-Sar-Leu. This implies that tripeptidomimetics originating from tripeptides with neutral side chains are more likely to be substrates for hPEPT1 than tripeptidomimetics with charged side chains. The results of the present study indicate that the N-methyl amide peptide bond replacement approach for increasing bioavailability of tripeptidomimetic drug candidates is not generally applicable to all tripeptides. Nevertheless, retained affinity for and transport via hPEPT1 were shown for three of the evaluated N-methyl amide tripeptidomimetics.
Collapse
Affiliation(s)
- Rikke Andersen
- Molecular Biopharmaceutics, Department of Pharmaceutics and Analytical Chemistry, The Danish University of Pharmaceutical Sciences, 2-Universitetsparken, DK-2100 Copenhagen, Denmark
| | | | | | | | | | | | | |
Collapse
|
8
|
Block P, Sotriffer CA, Dramburg I, Klebe G. AffinDB: a freely accessible database of affinities for protein-ligand complexes from the PDB. Nucleic Acids Res 2006; 34:D522-6. [PMID: 16381925 PMCID: PMC1347402 DOI: 10.1093/nar/gkj039] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
AffinDB is a database of affinity data for structurally resolved protein–ligand complexes from the Protein Data Bank (PDB). It is freely accessible at . Affinity data are collected from the scientific literature, both from primary sources describing the original experimental work of affinity determination and from secondary references which report affinity values determined by others. AffinDB currently contains over 730 affinity entries covering more than 450 different protein–ligand complexes. Besides the affinity value, PDB summary information and additional data are provided, including the experimental conditions of the affinity measurement (if available in the corresponding reference); 2D drawing, SMILES code and molecular weight of the ligand; links to other databases, and bibliographic information. AffinDB can be queried by PDB code or by any combination of affinity range, temperature and pH value of the measurement, ligand molecular weight, and publication data (author, journal and year). Search results can be saved as tabular reports in text files. The database is supposed to be a valuable resource for researchers interested in biomolecular recognition and the development of tools for correlating structural data with affinities, as needed, for example, in structure-based drug design.
Collapse
Affiliation(s)
| | | | | | - Gerhard Klebe
- To whom correspondence should be addressed. Tel: +49 6421 2821313; Fax: +49 6421 2828994;
| |
Collapse
|